CYP2D6

Cytochrome P450, family 2, subfamily D, polypeptide 6
	PDB基于2f9q的渲染图
有效结构
PDB	直系同源检索：PDBe, RCSB
PDB查询代码列表
	2F9Q, 3QM4, 3TBG, 3TDA, 4WNT, 4WNU, 4WNV, 4WNW
标识
代号	CYP2D6; CPD6; CYP2D; CYP2D7AP; CYP2D7BP; CYP2D7P2; CYP2D8P2; CYP2DL1; CYPIID6; P450-DB1; P450C2D; P450DB1
扩展标识	遗传学：124030 鼠基因：1929474 同源基因：133550 GeneCards: CYP2D6 Gene
EC編號	1.14.14.1
基因本体论描述
分子功能	· monooxygenase activity; · iron ion binding; · drug binding; · arachidonic acid epoxygenase activity; · steroid hydroxylase activity; · oxidoreductase activity; · oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen; · oxygen binding; · heme binding; · aromatase activity;
细胞成分	· cytoplasm; · mitochondrion; · endoplasmic reticulum; · endoplasmic reticulum membrane;
生物过程	· xenobiotic metabolic process; · steroid metabolic process; · coumarin metabolic process; · alkaloid metabolic process; · alkaloid catabolic process; · monoterpenoid metabolic process; · drug metabolic process; · arachidonic acid metabolic process; · isoquinoline alkaloid metabolic process; · drug catabolic process; · exogenous drug catabolic process; · small molecule metabolic process; · heterocycle metabolic process; · negative regulation of binding; · oxidation-reduction process; · oxidative demethylation; · negative regulation of cellular organofluorine metabolic process;
	Sources: Amigo / QuickGO
RNA表达模式
	更多表达数据
直系同源体

细胞色素 P450 2D6（英語：）是一种由人类CYP2D6基因编码的酶。CYP2D6主要在肝脏，并且也在中枢神经系统中，包括黑质。

CYP2D6是细胞色素P450混合功能氧化酶系统的成员之一，是人体中最重要的代谢酶之一。CYP2D6参与25%的临床药物的代谢和清除，过程主要是O-去甲基化。[1]CYP2D6也参与多种内源性物质的代谢，如5-羟色胺和神经类固醇。[1]

引用

Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF. . Drug Metab. Rev. 2009, 41 (4): 573–643. PMID 19645588. doi:10.1080/03602530903118729.

延伸閱讀

Smith G, Stubbins MJ, Harries LW, Wolf CR. . Xenobiotica. 1998, 28 (12): 1129–65. PMID 9890157. doi:10.1080/004982598238868.
Wolf CR, Smith G. . IARC Sci. Publ. 1999, (148): 209–29. PMID 10493260.
Ding X, Kaminsky LS. . Annu. Rev. Pharmacol. Toxicol. 2003, 43 (1): 149–73. PMID 12171978. doi:10.1146/annurev.pharmtox.43.100901.140251.
Lilienfeld S. . CNS Drug Rev. 2002, 8 (2): 159–76. PMID 12177686. doi:10.1111/j.1527-3458.2002.tb00221.x.
Yu AM, Idle JR, Gonzalez FJ. . Drug Metab. Rev. 2004, 36 (2): 243–77. PMID 15237854. doi:10.1081/DMR-120034000.
Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, Luccarini C, Shah M, Ingle S, Greenberg D, Earl HM, Dunning AM, Pharoah PD, Caldas C. . Breast Cancer Res. 2010, 12 (4): R64. PMC 2949659. PMID 20731819. doi:10.1186/bcr2629.
Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, Luccarini C, Earl HM, Dunning AM, Pharoah PD, Caldas C. . Cancer Epidemiol. Biomarkers Prev. 2011, 20 (6): 1255–8. PMID 21527579. doi:10.1158/1055-9965.EPI-11-0321.

外部連結

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid19645588-1] Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF. . Drug Metab. Rev. 2009, 41 (4): 573–643. PMID 19645588. doi:10.1080/03602530903118729.